The University of Chicago Header Logo

Connection

Susan L. Cohn to Neuroblastoma

Back to Details
This is a "connection" page, showing publications Susan L. Cohn has written about Neuroblastoma.
Susan L. Cohn
Connection Strength
21.038
Neuroblastoma
  1. Multimodality treatment for recurrent neuroblastoma in the central nervous system. Pediatr Blood Cancer. 2023 04; 70(4):e30227.
    View in: PubMed
    Score: 0.686
  2. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
    View in: PubMed
    Score: 0.656
  3. Rethinking high-risk neuroblastoma treatment. Pediatr Blood Cancer. 2022 08; 69(8):e29730.
    View in: PubMed
    Score: 0.650
  4. The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for 131I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. J Pediatr Hematol Oncol Nurs. 2022 Sep-Oct; 39(5):304-316.
    View in: PubMed
    Score: 0.638
  5. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform. 2020 10; 4:895-905.
    View in: PubMed
    Score: 0.584
  6. Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. Pediatr Blood Cancer. 2020 10; 67(10):e28390.
    View in: PubMed
    Score: 0.576
  7. 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clin Cancer Res. 2020 03 15; 26(6):1309-1317.
    View in: PubMed
    Score: 0.553
  8. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255.
    View in: PubMed
    Score: 0.539
  9. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516.
    View in: PubMed
    Score: 0.519
  10. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34.
    View in: PubMed
    Score: 0.477
  11. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.474
  12. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget. 2016 Nov 22; 7(47):76816-76826.
    View in: PubMed
    Score: 0.447
  13. Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. Oncotarget. 2016 Nov 22; 7(47):77696-77706.
    View in: PubMed
    Score: 0.447
  14. Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr. 2016 Feb; 28(1):19-25.
    View in: PubMed
    Score: 0.422
  15. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
    View in: PubMed
    Score: 0.410
  16. A Selfless Act. J Clin Oncol. 2015 Nov 10; 33(32):3834-5.
    View in: PubMed
    Score: 0.409
  17. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
    View in: PubMed
    Score: 0.384
  18. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Mol Oncol. 2014 May; 8(3):669-78.
    View in: PubMed
    Score: 0.368
  19. Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014 Jun; 61(6):1104-6.
    View in: PubMed
    Score: 0.363
  20. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9.
    View in: PubMed
    Score: 0.340
  21. Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. Pediatr Blood Cancer. 2013 Mar; 60(3):512-4.
    View in: PubMed
    Score: 0.337
  22. Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatr Blood Cancer. 2013 Feb; 60(2):332-5.
    View in: PubMed
    Score: 0.334
  23. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer. 2012 Jul 01; 58(7):1099-105.
    View in: PubMed
    Score: 0.322
  24. Locoregional MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2012 Oct; 59(4):736-8.
    View in: PubMed
    Score: 0.318
  25. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012 Oct; 59(4):642-7.
    View in: PubMed
    Score: 0.317
  26. Advances in the treatment of neuroblastoma. Clin Adv Hematol Oncol. 2011 Nov; 9(11):865-7.
    View in: PubMed
    Score: 0.315
  27. Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma. Pediatr Blood Cancer. 2012 Mar; 58(3):472-4.
    View in: PubMed
    Score: 0.302
  28. The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatr Blood Cancer. 2011 Jan; 56(1):164-7.
    View in: PubMed
    Score: 0.297
  29. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13.
    View in: PubMed
    Score: 0.295
  30. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 01; 29(1):76-82.
    View in: PubMed
    Score: 0.295
  31. Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111.
    View in: PubMed
    Score: 0.182
  32. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30735.
    View in: PubMed
    Score: 0.180
  33. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol. 2023 06 10; 41(17):3149-3159.
    View in: PubMed
    Score: 0.174
  34. Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 03 10; 41(8):1565-1576.
    View in: PubMed
    Score: 0.170
  35. MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074.
    View in: PubMed
    Score: 0.166
  36. Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188.
    View in: PubMed
    Score: 0.158
  37. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081.
    View in: PubMed
    Score: 0.155
  38. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 10 10; 39(29):3229-3241.
    View in: PubMed
    Score: 0.154
  39. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514.
    View in: PubMed
    Score: 0.154
  40. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
    View in: PubMed
    Score: 0.154
  41. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.154
  42. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189.
    View in: PubMed
    Score: 0.149
  43. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794.
    View in: PubMed
    Score: 0.147
  44. Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721.
    View in: PubMed
    Score: 0.145
  45. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. J Clin Oncol. 2020 11 01; 38(31):3685-3697.
    View in: PubMed
    Score: 0.145
  46. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020 08; 67(8):e28359.
    View in: PubMed
    Score: 0.143
  47. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918.
    View in: PubMed
    Score: 0.141
  48. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424.
    View in: PubMed
    Score: 0.136
  49. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755.
    View in: PubMed
    Score: 0.135
  50. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736.
    View in: PubMed
    Score: 0.132
  51. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2019 04; 66(4):e27556.
    View in: PubMed
    Score: 0.128
  52. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124.
    View in: PubMed
    Score: 0.128
  53. Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
    View in: PubMed
    Score: 0.127
  54. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149.
    View in: PubMed
    Score: 0.126
  55. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. Biol Blood Marrow Transplant. 2018 03; 24(3):452-459.
    View in: PubMed
    Score: 0.120
  56. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 01 01; 24(1):189-196.
    View in: PubMed
    Score: 0.119
  57. Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology. Virchows Arch. 2017 Oct; 471(4):553-557.
    View in: PubMed
    Score: 0.118
  58. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587.
    View in: PubMed
    Score: 0.115
  59. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. J Pediatr Oncol Nurs. 2017 May/Jun; 34(3):160-172.
    View in: PubMed
    Score: 0.113
  60. Data Commons to Support Pediatric Cancer Research. Am Soc Clin Oncol Educ Book. 2017; 37:746-752.
    View in: PubMed
    Score: 0.113
  61. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget. 2016 Dec 27; 7(52):87301-87311.
    View in: PubMed
    Score: 0.112
  62. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185.
    View in: PubMed
    Score: 0.112
  63. Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. Pediatr Blood Cancer. 2017 03; 64(3).
    View in: PubMed
    Score: 0.110
  64. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10.
    View in: PubMed
    Score: 0.109
  65. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56.
    View in: PubMed
    Score: 0.107
  66. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatr Blood Cancer. 2016 Jun; 63(6):1019-23.
    View in: PubMed
    Score: 0.106
  67. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12.
    View in: PubMed
    Score: 0.105
  68. Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma. Pediatr Blood Cancer. 2015 Dec; 62(12):2232-4.
    View in: PubMed
    Score: 0.102
  69. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63.
    View in: PubMed
    Score: 0.101
  70. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21.
    View in: PubMed
    Score: 0.099
  71. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9.
    View in: PubMed
    Score: 0.096
  72. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76.
    View in: PubMed
    Score: 0.096
  73. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Nov; 61(11):1932-9.
    View in: PubMed
    Score: 0.095
  74. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep. 2014 Jun 12; 7(5):1343-1352.
    View in: PubMed
    Score: 0.094
  75. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35.
    View in: PubMed
    Score: 0.093
  76. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer. 2014 Aug; 61(8):1350-6.
    View in: PubMed
    Score: 0.093
  77. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52.
    View in: PubMed
    Score: 0.092
  78. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6.
    View in: PubMed
    Score: 0.091
  79. Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer. 2014 May; 61(5):949-50.
    View in: PubMed
    Score: 0.091
  80. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Apr; 61(4):627-35.
    View in: PubMed
    Score: 0.090
  81. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 2013 Oct 15; 119(20):3718-26.
    View in: PubMed
    Score: 0.089
  82. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008.
    View in: PubMed
    Score: 0.089
  83. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8.
    View in: PubMed
    Score: 0.086
  84. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul; 48(7):947-52.
    View in: PubMed
    Score: 0.086
  85. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013 Jun; 60(6):985-93.
    View in: PubMed
    Score: 0.085
  86. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80.
    View in: PubMed
    Score: 0.084
  87. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 09; 107(8):1418-22.
    View in: PubMed
    Score: 0.084
  88. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
    View in: PubMed
    Score: 0.084
  89. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res. 2012 Sep 15; 72(18):4714-23.
    View in: PubMed
    Score: 0.083
  90. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013 Mar; 60(3):363-70.
    View in: PubMed
    Score: 0.082
  91. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8.
    View in: PubMed
    Score: 0.081
  92. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Nov 20; 29(33):4351-7.
    View in: PubMed
    Score: 0.078
  93. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64.
    View in: PubMed
    Score: 0.078
  94. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 01; 17(21):6858-66.
    View in: PubMed
    Score: 0.078
  95. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011 Aug 17; 103(16):1236-51.
    View in: PubMed
    Score: 0.077
  96. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011 Aug 20; 29(24):3286-92.
    View in: PubMed
    Score: 0.077
  97. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct; 261(1):243-57.
    View in: PubMed
    Score: 0.076
  98. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011 Mar; 47(4):561-71.
    View in: PubMed
    Score: 0.074
  99. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75.
    View in: PubMed
    Score: 0.073
  100. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23.
    View in: PubMed
    Score: 0.073
  101. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1324-34.
    View in: PubMed
    Score: 0.073
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.